http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#Head
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#assertion
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#provenance
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#pubinfo
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#assertion
http://purl.obolibrary.org/obo/DOID_9008
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9008
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB06674
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#association
http://www.w3.org/2000/01/rdf-schema#label
simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 1 1 active psoriatic arthritis psa alone or in combination with methotrexate 1 2 active ankylosing spondylitis as 1 3 moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 1 4 inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders simponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis simponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritis simponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6 mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 14 4
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB06674
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#provenance
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#pubinfo
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#sig
http://purl.org/nanopub/x/hasSignature
L72TTHMGh7gXWSvqLk1UfihWapyDYro1r2SIEyUDcf2XgK2naMOAoxRsyBynkZeSZvpLoVPxSleczxv6muYIgi8aeB4zvS+dXmD9RiC3YexWW/AOekvihRx5FJYY8RgN/iVar/RZgWkm3Wh3NA+OG4CKhvv1+fRcGl8EFwl9U5o=
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8
http://purl.org/dc/terms/created
2021-07-03T15:02:05.198+02:00
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs